Introduction
The American College of Cardiology (ACC) and the American Heart Association (AHA) released in 2017 guidelines for hypertension management, defining stage 1 hypertension based on lower thresholds (130-139/80-89 mm Hg). 1 Antihypertensive treatment is recommended for patients above those thresholds with previous cardiovascular disease (CVD) or related risk. Conversely, the 2013 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for hypertension management define stage 1 hypertension and the threshold to introduce antihypertensive medication based on systolic blood pressure (SBP) of 140-159 mm Hg or diastolic blood pressure (DBP) of 90-99 mm Hg. 2 From a public health perspective, there exists an interest in managing a larger number of individuals to prevent the deleterious effects of hypertension. 3 However, aggressive blood pressure (BP) treatment is also associated with adverse events and higher costs.
Hence, using data from the population-based CoLausjPsyCoLaus study, we contrasted the population impact of the 2017 ACC/AHA and 2013 ESH/ ESC guidelines.
Methods
Data were collected between 2014 and 2017 in 4438 participants (2448 women) aged 45-85 years. 5 Participants eligible for antihypertensive treatments were selected according to guidelines. Participants on BP-lowering treatment had their SBP and DBP levels increased by 10 and 5 mm Hg, respectively. 6 For the 2017 ACC/AHA approach, we stratified individuals according to their 10-year CVD risk, using original SBP and DBP values. 7 
Discussion
The 2017 ACC/AHA guidelines on hypertension management substantially increase the number of individuals eligible for antihypertensive treatment compared to the prevailing European guidelines, especially for 8, 9 were not considered and may influence the global costs. We thus recommend a careful evaluation of the cost-effectiveness of the 2017 ACC/AHA guidelines before any implementation, especially in Europe.
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